Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2018 | Novel ventoclax combinations for CLL

Eva Kimby • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Obinutuzumab Venetoclax

The future of chronic lymphocytic leukemia (CLL) treatment is bright and looking towards novel combinations. Here, Eva Kimby, MD, PhD, of the Karolinska University Hospital, Solna, Sweden, gives us her thoughts on promising novel therapies, including venetoclax combinations. This interview took place at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

More from Eva Kimby

1:25
A perspective on MRD in CLL: treatment efficacy, early relapse detection & more
Eva Kimby • 25 Oct 2018
2:11
A perspective on the current landscape of CLL treatment
Eva Kimby • 25 Oct 2018

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals